These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...
The JV will focus on discovering and developing new drugs for conditions ... of blindness called Stargardt. Bayer is just the latest in a string of big pharma companies to invest in firms with ...
Unfortunately, a year after the rollout of DSO, Bayer’s headaches ... the launch of Nubeqa - a drug that’s already generated over $1 billion USD. The company offers a complex portfolio ...
Notably, the company warned that 2025 will be weaker ... Sales of glyphosate-based herbicides declined by 19% YoY. Meanwhile, Bayer's Pharmaceutical division has delivered mixed performance.
(Bloomberg) -- Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the company still faces after its $63 billion acquisition of ...
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an interview published on ...
Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling ... Calif., biotechnology company has acoramidis’ U.S. rights, added the story… Published first on ...
This along with the current drug shortage will support the revenue growth of pharma companies in the coming ... Eylea sold by Regeneron and Bayer, Bristol Myers Squibb’s Opdivo (nivolumab ...
Bayer expects its pharmaceutical business to return to growth in 2027, unit President Stefan Oelrich said Monday. The German conglomerate is planning to launch new therapies — one that treats a ...
Bayer BAYN1.13%increase ... a win for the German pharmaceutical and agricultural conglomerate that still faces litigation in the U.S. The group has been hounded by lawsuits since 2018 when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback